More on URGN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+92.8% Growth)
- Ratings (7.7 Score)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

UroGen Pharma (NQ:URGN)
Delayed: 43.30 +0.21 (0.49%)
Prev. Close $43.09  
Open$42.59 
52 Wk High$ 
52 Wk Low$ 
Day High$43.46 
Day Low$42.52 
P/E N/A  
EPS$ 
Volume159,484 

Friends, Peers and Foes (?): ABBV, ARGX, ARWR, BBIO, CGON (more...)

Aug 28, 2026 04:02 PM Form 4 UroGen Pharma Ltd. For: Aug 26 Filed by: Robinson James A. Jr.
Aug 24, 2026 05:03 PM Form 4 UroGen Pharma Ltd. For: Aug 20 Filed by: Schoenberg Mark
Aug 20, 2026 01:25 PM Form 144 UroGen Pharma Ltd. Filed by: Schoenberg Mark
Aug 20, 2026 07:06 AM UroGen to invest $7M in IntraGel for head and neck cancer therapy
Aug 20, 2026 07:05 AM Form 8-K UroGen Pharma Ltd. For: Aug 18
Aug 20, 2026 07:05 AM IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
Aug 20, 2026 07:00 AM UroGen strikes option deal with IntraGel, invests up to $7M
Aug 20, 2026 07:00 AM UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
Aug 20, 2026 06:57 AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Aug 17, 2026 08:04 AM UroGen files NDA with FDA for bladder cancer drug UGN-103
View All Articles

Entities mentioned with URGN

View All Entities